Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 91 to 100 of 903

TitleReference numberPublishedLast updated
Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodiesTA1073
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancerTA1071
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA1072
Spesolimab for treating generalised pustular psoriasis flaresTA1070
Linzagolix for treating symptoms of endometriosisTA1067
Efgartigimod for treating antibody-positive generalised myasthenia gravisTA1069
Somapacitan for treating growth hormone deficiency in people 3 to 17 yearsTA1066
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal)TA1068
Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA1065
Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA1064

Results per page

  1. 10
  2. 25
  3. 50
  4. All